Roche lung cancer drug misses endpoint

Country

Switzerland

A Phase 3 trial of a potential first line therapy for a type of small cell lung cancer which has spread to other parts of the body, failed to meet its co-primary endpoint of progression free survival, the developer Roche announced on 30 March.

The trial was testing tiragolumab, an antibody targeting the immune checkpoint TIGIT, together with Tecentriq (atezolizumab) and chemotherapy. The combination therapy was compared with Tecentriq and chemotherapy alone in 490 people with extensive-stage small cell lung cancer.